Altogether, these data highlight the dysregulation of LAG-3 on leukemic cells and provide new insights into the relevance of LAG-3 dysregulation in the clinical outcome of patients with CLL, hence suggesting that it may be involved in the suppression of the immune response in this malignancy. The gene discussed is LAG3; the disease is B-cell chronic lymphocytic leukemia.